InspireMD (STU:II2) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:II2 InspireMD Inc STU:II2
48 GF Score
Price €0.62
GF Value €1.51
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

STU:II2
48GF Score
InspireMD Inc STU:II2
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.62 is trading 59.3% below its estimated GF Value™ of €1.51. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Interest Expense (Positive):
  • GF Value™: €1.51 vs. price of €0.62 (59.3% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
48GF Score

Get the complete analysis for STU:II2

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price
€1.51
GF Value